Hemogenyx Pharmaceuticals PLC Announces Ultrafast CAR-T Manufacturing
Hemogenyx Pharmaceuticals (LSE:HEMO) has announced a strategic collaboration with Kure.ai to develop an ultrafast manufacturing process for CAR-T cell therapies targeting acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL). The partnership will integrate Kure's ultrafast manufacturing (UM) technology with Hemogenyx's proprietary HG-CT-1 therapy.
The collaboration includes initiating a clinical study, developing a customized UM process, sharing materials and expertise, conducting in vitro testing, and adapting manufacturing technology. Hemogenyx will have the option to license Kure's UM technology for clinical trial production upon successful development.
This partnership aims to address key challenges in CAR-T therapy production by reducing manufacturing timelines while maintaining therapeutic potency, ultimately accelerating patient access to treatment.
Hemogenyx Pharmaceuticals (LSE:HEMO) ha annunciato una collaborazione strategica con Kure.ai per sviluppare un processo di produzione ultrarapido per terapie con cellule CAR-T mirate alla leucemia mieloide acuta (AML) e alla leucemia linfoblastica acuta (ALL). Il partenariato integrerà la tecnologia di produzione ultrarapida (UM) di Kure con la terapia proprietaria di Hemogenyx, HG-CT-1.
La collaborazione prevede l'avvio di uno studio clinico, lo sviluppo di un processo UM personalizzato, la condivisione di materiali ed esperienze, la conduzione di test in vitro e l'adattamento della tecnologia di produzione. Hemogenyx avrà l'opzione di acquisire in licenza la tecnologia UM di Kure per la produzione nei trial clinici dopo un sviluppo riuscito.
Questa partnership mira a affrontare le principali sfide nella produzione di terapie CAR-T riducendo i tempi di produzione mantenendo la potenza terapeutica, accelerando infine l'accesso dei pazienti al trattamento.
Hemogenyx Pharmaceuticals (LSE:HEMO) ha anunciado una colaboración estratégica con Kure.ai para desarrollar un proceso de fabricación ultrarrápido para terapias con células CAR-T dirigidas a la leucemia mieloide aguda (AML) y la leucemia linfoblástica aguda (ALL). La asociación integrará la tecnología de fabricación ultrarrápida (UM) de Kure con la terapia propietaria de Hemogenyx, HG-CT-1.
La colaboración incluye el inicio de un estudio clínico, el desarrollo de un proceso UM personalizado, el intercambio de materiales y experiencia, la realización de pruebas in vitro y la adaptación de la tecnología de fabricación. Hemogenyx tendrá la opción de licenciar la tecnología UM de Kure para la producción en ensayos clínicos tras un desarrollo exitoso.
Esta asociación tiene como objetivo abordar los principales desafíos en la producción de terapias CAR-T reduciendo los tiempos de fabricación mientras se mantiene la potencia terapéutica, acelerando así el acceso de los pacientes al tratamiento.
Hemogenyx Pharmaceuticals (LSE:HEMO)는 Kure.ai와 협력하여 급성 골수성 백혈병 (AML) 및 급성 림프아구 백혈병 (ALL)을 표적으로 하는 CAR-T 세포 치료제를 위한 초고속 제조 공정을 개발한다고 발표했습니다. 이 파트너십은 Kure의 초고속 제조(UM) 기술을 Hemogenyx의 독점 치료제인 HG-CT-1과 통합할 것입니다.
협력은 임상 연구 시작, 맞춤형 UM 공정 개발, 소재 및 전문 지식 공유, 시험관 내 테스트 수행, 제조 기술 조정을 포함합니다. Hemogenyx는 성공적인 개발 후 임상 시험 생산을 위해 Kure의 UM 기술을 라이센스 받을 수 있는 옵션을 갖게 됩니다.
이 파트너십은 CAR-T 치료제 생산의 주요 과제를 해결하기 위해 제조 시간을 단축하면서 치료 효능을 유지하는 것을 목표로 하며, 궁극적으로 환자의 치료 접근성을 가속화하는 것을 목표로 합니다.
Hemogenyx Pharmaceuticals (LSE:HEMO) a annoncé une collaboration stratégique avec Kure.ai pour développer un processus de fabrication ultrarapide pour les thérapies par cellules CAR-T ciblant la leucémie myéloïde aiguë (AML) et la leucémie lymphoblastique aiguë (ALL). Ce partenariat intégrera la technologie de fabrication ultrarapide (UM) de Kure avec la thérapie propriétaire de Hemogenyx, HG-CT-1.
La collaboration inclut le lancement d'une étude clinique, le développement d'un processus UM personnalisé, le partage de matériaux et d'expertise, la réalisation de tests in vitro et l'adaptation de la technologie de fabrication. Hemogenyx aura la possibilité de licencier la technologie UM de Kure pour la production d'essais cliniques après un développement réussi.
Cette partenariat vise à relever les principaux défis liés à la production de thérapies CAR-T en réduisant les délais de fabrication tout en maintenant la puissance thérapeutique, accélérant ainsi l'accès des patients au traitement.
Hemogenyx Pharmaceuticals (LSE:HEMO) hat eine strategische Zusammenarbeit mit Kure.ai angekündigt, um einen ultraschnellen Herstellungsprozess für CAR-T-Zelltherapien zu entwickeln, die auf akute myeloische Leukämie (AML) und akute lymphoblastische Leukämie (ALL) abzielen. Die Partnerschaft wird Kures ultraschnelle Herstellungstechnologie (UM) mit Hemogenyx' proprietärer Therapie HG-CT-1 integrieren.
Die Zusammenarbeit umfasst den Beginn einer klinischen Studie, die Entwicklung eines maßgeschneiderten UM-Prozesses, den Austausch von Materialien und Fachwissen, die Durchführung von In-vitro-Tests und die Anpassung der Herstellungstechnologie. Hemogenyx hat die Möglichkeit, Kures UM-Technologie für die Produktion klinischer Studien nach erfolgreicher Entwicklung zu lizenzieren.
Diese Partnerschaft zielt darauf ab, die wichtigsten Herausforderungen in der Produktion von CAR-T-Therapien zu bewältigen, indem die Herstellungszeiten verkürzt werden, während die therapeutische Wirksamkeit erhalten bleibt, um letztendlich den Patienten den Zugang zur Behandlung zu erleichtern.
- None.
- None.
Collaboration with Kure.ai to develop ultrafast CAR-T manufacturing process for Hemogenyx Pharmaceuticals' AML Treatment
LONDON, UNITED KINGDOM / ACCESSWIRE / December 19, 2024 / Hemogenyx Pharmaceuticals plc (LSE:HEMO), the biopharmaceutical company developing innovative therapies for blood malignancies, and Kure.ai ("Kure"), a leader in ultrafast CAR-T manufacturing technology, are pleased to announce a strategic collaboration to advance the production of CAR-T cell therapies for acute myeloid leukemia (AML) and a subset of acute lymphoblastic leukemia (ALL).
This partnership aims to integrate Kure's ultrafast manufacturing (UM) technology with Hemogenyx Pharmaceuticals's proprietary CAR-T therapy, HG-CT-1 (formerly known as HEMO-CAR-T) to enable faster, more efficient production of CAR-T cells, significantly reducing manufacturing timelines while maintaining therapeutic potency.
Key Highlights of the Collaboration
Clinical Study:
Hemogenyx Pharmaceuticals will initiate a clinical study to evaluate its CAR-T therapy for AML and KMT2A-rearranged ALL, utilizing Kure's UM process.Process Development:
Both parties will collaborate on developing a customized UM process for Hemogenyx Pharmaceutical's CAR-T therapy, optimizing its application in AML treatment.Material and Expertise Sharing:
Hemogenyx Pharmaceuticals will provide critical materials, including lentiviral vectors, and necessary technical know-how to facilitate process development.In Vitro Testing:
Hemogenyx Pharmaceuticals will conduct in vitro testing to assess the potency and vector copy number (VCN) of CAR-T cells manufactured using Kure's ultrafast platform.Adaptation of Manufacturing Technology:
Kure will adapt and refine its ultrafast CAR-T manufacturing process specifically to the Company's CAR-T therapy requirements.Licensing Option:
Upon successful completion of process development, Hemogenyx Pharmaceuticals will have the option to license Kure's UM technology for clinical trial production, with licensing terms to be negotiated.
Dr. Vladislav Sandler, CEO & Co-Founder of Hemogenyx Pharmaceuticals, commented:
"One of the most significant challenges in CAR-T therapy is the time and cost associated with manufacturing. Our partnership with Kure.ai allows us to explore and integrate a cutting-edge ultrafast manufacturing process that has the potential to revolutionize CAR-T production. This collaboration is an important step toward accelerating patient access to life-saving therapies."
Dr. David Wald, Founder of Kure.ai and Professor at Case Western Reserve University, added:
"We are excited to partner with Hemogenyx Pharmaceuticals to adapt our ultrafast manufacturing platform to their innovative CAR-T therapy. This collaboration not only advances next-generation CAR-T solutions but also demonstrates the real-world clinical utility of our technology in addressing urgent unmet medical needs."
About AML and CAR-T Therapy
AML, the most common type of acute leukemia in adults, has poor survival rates (a five-year survival rate of less than
CAR-T therapy is a treatment in which a patient's own T-cells, a type of immune cell, are modified to recognize and kill the patient's cancer cells. The procedure involves: isolating T-cells from the patient; modifying the isolated T-cells in a laboratory using a CAR gene construct (which allows the cells to recognize the patient's cancer); amplifying (growing to large numbers) the newly modified cells; and re-introducing the cells back into the patient.
Market Abuse Regulation (MAR) Disclosure
Certain information contained in this announcement would have been inside information for the purposes of Article 7 of Regulation No 596/2014 (as it forms part of UK domestic law by virtue of the European Union (Withdrawal) Act 2018) until the release of this announcement. The person responsible for arranging for the release of this announcement on behalf of Hemogenyx Pharmaceuticals plc is Dr Vladislav Sandler, Chief Executive Officer & Co-Founder.
Enquiries:
Hemogenyx Pharmaceuticals plc | |
Dr Vladislav Sandler, Chief Executive Officer & Co-Founder | |
Peter Redmond, Director | |
|
|
SP Angel Corporate Finance LLP | Tel: +44 (0)20 3470 0470 |
Matthew Johnson, Vadim Alexandre, Adam Cowl |
|
|
|
Peterhouse Capital Limited | Tel: +44 (0)20 7469 0930 |
Lucy Williams, Duncan Vasey, Charles Goodfellow |
|
About Hemogenyx Pharmaceuticals plc
Hemogenyx Pharmaceuticals is a publicly traded company (LSE:HEMO) headquartered in London, with its US operating subsidiaries, Hemogenyx Pharmaceuticals LLC and Immugenyx LLC, located in New York City at its state-of-the-art research facility.
The Company is a clinical stage biopharmaceutical group developing new medicines and treatments to treat blood and autoimmune disease and to bring the curative power of bone marrow transplantation to a greater number of patients suffering from otherwise incurable life-threatening diseases. Hemogenyx Pharmaceuticals is developing several distinct and complementary product candidates, as well as a platform technology that it uses as an engine for novel product development.
About Kure.ai
Kure.ai is a clinical stage privately owned biotechnology company specializing in ultrafast CAR-T manufacturing technology. Founded by Dr. David Wald, a professor at Case Western Reserve University, Kure focuses on optimizing CAR-T production timelines while maintaining therapeutic quality and efficacy.
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
SOURCE: Hemogenyx Pharmaceuticals PLC
View the original press release on accesswire.com
FAQ
What is the purpose of Hemogenyx and Kure.ai's collaboration for CAR-T manufacturing?
What are the key components of Hemogenyx's CAR-T manufacturing partnership announced in December 2024?
How will the Kure.ai partnership improve Hemogenyx's CAR-T therapy production?
What types of cancer does Hemogenyx's CAR-T therapy target?
What testing will be conducted for the new CAR-T manufacturing process?
